Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Thirty drug-free depressed patients underwent double-blind, placebo-controlled, neuroendocrine testing with the serotonin (5-HT) releasing agent d-fenfluramine prior to receiving treatment with a selective serotonin reuptake inhibitor (SSRI) for 8 weeks. Compared to placebo, d-fenfluramine significantly elevated plasma levels of prolactin and cortisol, increased subjective visual analogue ratings of "light headed" and decreased ratings of "desire to eat". Of the 30 patients studied, 17 responded to treatment but none of the pretreatment responses to d-fenfluramine distinguished patients who responded to SSRI treatment from those who did not. The results suggest that the clinical response to SSRI administration may be independent of pretreatment brain 5-HT function. Another possibility is that the neuroendocrine and subjective effects of d-fenfluramine are mediated by 5-HT mechanisms other than those involved in the antidepressant effect of SSRIs.


Journal article


Int Clin Psychopharmacol

Publication Date





215 - 220


Adolescent, Adult, Depressive Disorder, Double-Blind Method, Female, Fenfluramine, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Serotonin Uptake Inhibitors